1222633-85-3

Usage

Uses

Used in Pharmaceutical Industry:
2-(chloroMethyl)-3,5-difluoropyridine is utilized as a key intermediate in the synthesis of pharmaceutical agents. Its unique structure allows for the development of novel drug candidates with specific therapeutic properties, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(chloroMethyl)-3,5-difluoropyridine is employed as a precursor in the production of fungicides and herbicides. Its incorporation into these products enhances their effectiveness in controlling pests and diseases, thereby supporting agricultural productivity and crop protection.
Used as a Building Block in Organic Chemistry:
2-(chloroMethyl)-3,5-difluoropyridine serves as a valuable building block in organic chemistry for the synthesis of a variety of chemical compounds. Its versatile structure facilitates the creation of diverse chemical products, expanding the scope of applications in different industries.

Upstream product

• 955885-64-0 methyl 3,5-difluoropyridine-2-carboxylate 
• 1065267-14-2 (3,5-difluoro-pyridin-2-yl)-methanol 
• 745784-04-7 3,5-difluoropyridine-2-carboxylic acid 
• 1065267-10-8 3,5-difluoro-pyridine-2-carboxylic acid ethyl ester 

Downstream Products

• 1442451-89-9 5-chloro-6-((3,5-difluoropyridin-2-yl)methoxy)-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-2-methylphenyl)-2-methylpyrimidin-4(3H)-one 

Relevant academic research and scientific papers

PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS

The present disclosure provides a crystalline form of the methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compound of the structure: XRPD, TGA, and DSC data on the crystalline form, as well as methods preparing the crystalline form, inclu

PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS

Pyrido[2,3-d]pyrimidin-4-one compounds, formulations containing those compounds, and their use as tankyrase 1 and 2 inhibitors Formula (I).

METHYL/FLUORO-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS AND FLUORO-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS

The present disclosure provides methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and auto-inflammatory disease, including rheumatoid arthritis, having the structure of Formula (I): wherein R1, R2, R3, R4, R5 and X are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.

SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS

The present disclosure provides pyrimidinone-phenyl-pyrimidinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and inflammatory disease, having the structure of Formula (I): wherein R1, R2, R3, R4 and R5 are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.

FAAH INHIBITORS

The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the com